secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001613103-25-000078
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic Q4 EPS $1.62 non-GAAP (+11%); to spin off Diabetes; dividend raised to $0.71
--------------------------------------------------------------------------------

- Q4 FY25 revenue $8.93B (+5.4% organic); non-GAAP EPS $1.62 (+11% as reported, +16% constant currency).
- Plans to spin off Diabetes business into standalone public company within 18 months via IPO/split-off; accretive to margins and EPS.
- Dividend raised to $0.71/quarter ($2.84 annual) — 48th consecutive annual increase; payable July 11, 2025.
- Sean Salmon departs as EVP Cardiovascular; Skip Kiil promoted to EVP/President Cardiovascular Portfolio; Michael Carter to lead CST.
- FY26 guidance: ~5% organic revenue growth; non-GAAP EPS $5.50-$5.60 reflecting tariff uncertainty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/0001613103-25-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/mdt-20250521.htm
  HTML page:      https://secwatch.observer/filing/0001613103-25-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer